Allergan Plc (AGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Summary

Allergan Plc (Allergan) is a specialty pharmaceutical company that develops and sells branded pharmaceuticals, biosimilar and over-the-counter (OTC) pharmaceutical products. It offers products in the areas of eye care, medical aesthetics, dermatology, central nervous system, gastroenterology, womens health, urology and anti-infective therapeutic categories. The company sells its products to retailers, drug wholesalers and distributors, including national retail drug and food store chains, mail order retailers, hospitals, clinics, government agencies and managed healthcare providers such as health maintenance organizations and other institutions. It has operations in several countries across the Americas, Europe, Asia-Pacific, the Middle East and Africa. Allergan is headquartered in Dublin, Ireland.

Allergan Plc (AGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

2
List of Tables 9
List of Figures 14
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 15
Allergan Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 16
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 17
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 18
Allergan Plc, Medical Devices Deals, 2011 to YTD 2017 20
Allergan Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 21
Allergan Plc, Pharmaceuticals & Healthcare, Deal Details 35
Asset Purchase 35
Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 35
Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 35
Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 37
Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For US$55 Million 38
Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 39
Watson Pharma Acquires Generic Pharma Products From Perrigo 40
Forest Labs Acquires Worldwide Rights Of Azimilide From Blue Ash Therapeutics 41
Allergan Acquires Distribution Business from Genop Healthcare 42
Venture Financing 43
Chase Pharma Raises USD12 Million in Financing Round 43
Chase Pharma Raises Additional USD0.5 Million in Venture Financing 43
Akarna Therapeutics Raises USD15 Million in Series B Financing 44
RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 45
Chase Pharma Raises USD3 Million in Venture Financing 46
RetroSense Therapeutics Raises USD6 Million in Series A Financing 46
Naurex Raises USD80 Million in Series C Venture Financing 47
Colorescience Raises USD15 Million in Series B Venture Financing 48
Chase Pharma Raises USD21 Million in Series B Financing 49
Naurex Raises US$25 Million In Venture Financing 50
Topokine Therapeutics Raises Funds Through Venture Financing 51
Colorescience Raises US$10 Million In Series A Financing 52
Anterios Raises US$8.5 Million In Venture Financing 53
Anterios Raises US$4.7 Million In Venture Financing 54
Topokine Therapeutics Raises Funds Through Venture Financing 54
Colorescience Raises US$15 Million In Venture Financing 55
Regado Biosciences Raises US$51 Million In Series E Financing 55
Naurex Raises US$38 Million In Series B Financing 57
Uteron Pharma Raises US$10.4 Million In Venture Financing 59
Regado Biosciences Raises US$6.8 Million In Venture Financing 59
Uteron Pharma Raises US$19 Million In Venture Financing 60
SkinMedica Raises US$16.8 Million In Venture Financing 61
KYTHERA BioPharma Secures US$37.42 Million In Series D Financing Round 62
Anterios Secures US$3.1 Million In Venture Financing 63
Regado Biosciences Secures US$11.6 Million In Financing 64
Naurex Secures US$18 Million In Series A Financing Round 64
RetroSense Therapeutics Secures US$0.07 Million In Venture Financing 65
Chase Pharma Secures US$1.2 Million In Venture Financing 66
Private Equity 66
TPG Capital Acquires Aptalis Pharma from Actavis 66
VMG Partners Invests In Colorescience 67
SRIW Invests US$2 Million In Uteron Pharma 68
Partnerships 69
Allergan to Enter into Partnership with Target PharmaSolutions 69
Allergan Enters into Agreement with Novartis 69
Gedeon Richter Enters into Distribution Agreement with Allergan 70
T2 Biosystems Enters into Agreement with Allergan 71
Amgen Enters into Agreement with Allergan 71
Allergan Enters into Co-Development Agreement with AstraZeneca 72
Galderma Enters into Agreement with ZELTIQ Aesthetics 73
Allergan Enters into Agreement with Rugen Therapeutics 74
Allergan Enters into Research Agreement with Humana 74
NuMedii Enters into Research Agreement with Allergan 75
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 76
Molecular Partners Reinforces Partnership with Allergan 77
Allergan Enters into Distribution Agreement with WhanIn Pharma 77
Particle Sciences Enters Into Co-Development Agreement With Actavis 78
Voyant Biotherapeutics Enters Into R&D Agreement With Allergan For Ocular Disease 79
Merrimack Pharma Enters Into Co-Development Agreement With Actavis 80
Amerigen Pharma Enters Into Co-Development Agreement With Forest Labs For Specialty Generic Products 81
Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 81
Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 82
Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 83
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 83
Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 84
Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 85
Allergan Enters Into Co-Development Agreement With Molecular Partners 86
Forest Labs Enters Into Co-Development Agreement With Nabriva Therapeutics For BC-3781 87
American Medical Systems Enters Into Co-Development Agreement With Allergan 88
ACADIA Pharma Extends Co-Development Agreement With Allergan 89
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 89
ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 90
Amgen Enters Into Co-Development Agreement With Watson For Generic Cancer Drugs 91
ExonHit Extends Co-Development Agreement With Allergan 93
ACADIA Pharma Extends Drug Discovery Collaboration With Allergan 93
Allergan Enters Into Co-Promotion Agreement With MAP Pharma 94
Merger 95
Regado Biosciences Merges with Tobira Therapeutics 95
Licensing Agreements 96
Allergan Enters into Licensing Agreement with Assembly Biosciences 96
Allergan Enters into Licensing Agreement with UroGen Pharma 97
Durata Therapeutics Enters into Licensing Agreement with Angelini for Dalvance 98
Forest Labs Enters Into Licensing Agreement With Adamas Pharma For CNS Drug 100
Allergan Enters into Licensing Agreement with AstraZeneca 101
RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 102
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 102
Angelini Enters into Licensing Agreement with Allergan 103
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 104
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 105
Allergan Enters into Licensing Agreement with Heptares Therapeutics 106
Allergan Enters into Licensing Agreement with Mimetogen Pharma 108
Allergan Enters into Licensing Agreement with Almirall for Constella 109
Apricus Biosciences Enters into Licensing Agreement with Allergan 109
Allergan Enters into Licensing Agreement with Merck 110
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 111
Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 112
Kythera Biopharma Terminates Licensing Agreement With Intendis For ATX-101 113
Allergan Enters Into Licensing Agreement With Medytox For Neurotoxin Product 114
Forest Labs Amends Licensing Agreement With moksha8 For Viibryd 115
InnoCore Enters Into Licensing Agreement With Allergan 116
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 117
RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 118
Topokine Therapeutics Enters into Licensing Agreement with University of Bristol 118
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 119
Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 120
Watson Pharma Enters Into Licensing Agreement With moksha8 Pharma For Five Generic Central Nervous System Products 121
Forest Labs Enters Into Licensing Agreement With moksha8 For Viibryd 122
Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 123
Allergan Enters Into Licensing Agreement With Molecular Partners 124
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 125
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 126
QrxPharma Enters Into Licensing Agreement With Actavis For MoxDuo IR 127
Furiex Enters Into Licensing Agreement With Janssen Pharmaceutica For MuDelta 129
RetroSense Therapeutics Enters Into Licensing Agreement With Wayne State University 130
Watson Pharma Enters Into Licensing Agreement With Antares Pharma For Anturol 131
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 132
Allergan Enters Into Licensing Agreement With Molecular Partners For MP0112 132
Durata Therapeutics Enters Into Licensing Agreement For Dalbavancin 133
Furiex Pharma Enters Into Licensing Agreement With Janssen Pharmaceutica For JNJ-Q2 134
Indoco Remedies Extends Licensing Agreement With Watson Pharma For Sterile Products 135
Biovail Labs Enters Into Licensing Agreement With Allergan For Aczone 136
Equity Offering 137
Vitae Pharma Raises USD35 Million in Public Offering of Shares 137
Aptinyx Spin Off from Naurex 139
Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 139
Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 140
Anterios Postpones IPO for up to USD54.6 Million 141
Kythera Biopharma Raises USD143.8 Million in Public Offering of Shares 142
Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 144
Actavis Raises USD4.18 Billion in Public Offering of Shares 145
Vitae Pharma Raises USD41 Million in Public Offering of Shares 147
Vitae Pharmaceuticals Completes Exercise of Underwriters Over Allotment Option for IPO for USD63.3 Million 149
Tobira Therapeutics Withdraws IPO 150
Regado Biosciences Completes Public Offering Of Shares For US$60 Million 152
Regado Biosciences Completes Private Placement Of Shares For US$20 Million 153
Furiex Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 154
Kythera Biopharma Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For US$133.5 Million 155
Regado Biosciences Completes Underwriters Exercise Of Over-Allotment Option For IPO For US$43 Million 156
Durata Therapeutics Completes Public Offering Of Shares For US$58 Million 157
Kythera Biopharma Completes Underwriters Exercise Of Over-Allotment Option For US$81 Million 158
MAP Pharma Completes Public Offering Of Common Stock For US$60 Million 160
Forest Labs Plans Rights Offering Of Common Stock 161
Durata Therapeutics Completes IPO For US$78 Million 161
Debt Offering 162
Allergan Raises USD817.8 Million in Public Offering of 0.5% Notes Due 2021 162
Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 163
Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 165
Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 166
Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 167
Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2045 168
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2016 170
Actavis Raises USD4 Billion in Public Offering of Senior Notes Due 2025 172
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2020 174
Actavis Raises USD1 Billion in Public Offering of Senior Notes Due 2017 176
Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2022 178
Actavis Raises USD3.5 Billion in Public Offering of Senior Notes Due 2020 180
Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2035 182
Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2018 184
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2018 186
Forest Lab Completes Private Placement Of Notes Due 2021 For US$750 Million 188
Forest Lab Completes Private Placement Of Notes Due 2019 For US$1.05 Billion 188
Forest Labs Completes Private Placement Of Notes Due 2021 For US$1.2 Billion 189
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 190
Watson Pharma Completes Public Offering Of Notes Due 2022 For US$1.7 Billion 191
Watson Pharma Completes Public Offering Of Notes Due 2017 For US$1.2 Billion 192
Watson Pharma Completes Public Offering Of Notes Due 2042 For US$1 Billion 193
Asset Transactions 195
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 195
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 196
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 198
AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 200
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 201
Impax Labs Acquires Two Generic Products from Actavis 202
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 203
G&W Labs Acquires Facility in Lincoln County, North Carolina from Actavis 204
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 204
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 206
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To US$110 Million 207
Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 209
Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 210
Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 211
Harvard Drug Group Completes Acquisition Of Rugby OTC Portfolio Of Watson Pharma For US$117 Million 212
Acquisition 213
Allergan Enters into Option Arrangement to Acquire Lysosomal Therapeutics 213
Allergan Acquires Motus Therapeutics 214
Allergan Acquires Chase Pharma 215
Allergan Acquires Tobira Therapeutics in Tender Offer 216
Allergan Acquires Vitae Pharma in Tender Offer 218
Teva Pharma Acquires Anda from Allergan for USD500 Million 220
Allergan Acquires Akarna Therapeutics 221
Allergan Acquires RetroSense Therapeutics 222
Allergan to Acquire ForSight VISION5 223
Allergan Acquires Topokine Therapeutics 224
Allergan Acquires Anterios 224
Allergan Acquires Kythera Biopharma for USD2.1 Billion 225
Allergan Acquires Naurex for USD560 Million 227
Actavis Acquires Auden Mckenzie for USD458 Million 228
Actavis Acquires Allergan for USD70.5 Billion 229
Actavis May Acquire Almirall 230
Actavis Acquires Durata Therapeutics for USD675 Million in Tender Offer 231
Pfizer May Acquire Actavis 233
Forest Labs Completes Acquisition of Furiex Pharma 234
Actavis Completes Acquisition of Forest Labs for USD28 Billion 235
Actavis Acquires Silom Medical For US$100 Million 237
Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For US$2.9 Billion 238
Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 240
AstraZeneca Rumored To Acquire Forest Labs For US$15 Billion 241
Actavis Completes Acquisition Of Warner Chilcott For US$8.5 Billion 241
Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To US$9.1 Million 244
Allergan Completes Acquisition Of MAP Pharma For US$958 Million 245
Watson Pharma Acquires Uteron Pharma, Womens Health Company, For Up To US$305 Million 246
Allergan Completes Acquisition Of SkinMedica, Skin Products Maker, For US$350 Million 248
Watson Pharma Completes Acquisition Of Actavis Group For US$5.92 Billion 250
Watson Pharma Sells Minority Stake In moksha8 Pharma For US$47 Million 252
Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For US$394 Million 253
SkinMedica Acquires Colorescience, Maker Of Skincare Products 255
Allergan Completes Acquisition Of Vicept Therapeutics 256
High River Acquires 6.5% Stake In Forest Labs 257
Watson Pharma Acquires Specifar Pharma 257
Forest Labs Completes Acquisition Of Clinical Data 259
Allergan Plc - Key Competitors 262
Key Employees 263
Locations And Subsidiaries 264
Head Office 264
Other Locations & Subsidiaries 264
Recent Developments 273
Strategy And Business Planning 273
Aug 09, 2016: EDA Board Acts to Encourage Global Pharmaceutical Company Allergan to Expand in New Jersey 273
Apr 25, 2016: Allergan Breaks Ground on $200 Million Waco Facility Expansion 274
Financial Announcements 275
May 09, 2017: Allergan Reports Solid Start to 2017 with 5% Increase in First Quarter GAAP Net Revenues to $3.6 Billion 275
Feb 08, 2017: Allergan Reports Strong 2016 Finish with 7% Increase in GAAP Net Revenues to $3.9 Billion in Fourth Quarter 2016 279
Nov 02, 2016: Allergan Reports Third Quarter 2016 Continuing Operations Performance with GAAP Net Revenues of $3.6 Billion; Announces Accelerated Share Repurchase, Initiation of Cash Dividend 284
Aug 08, 2016: Allergan Reports Strong Second Quarter 2016 Continuing Operations Performance with Net Revenues of $3.7 Billion 288
May 10, 2016: Allergan Reports Strong First Quarter 2016 Continuing Operations Performance with 48% Increase in Net Revenue to $3.8 Billion and 15% Growth in Non-GAAP Diluted EPS to $3.04 292
Feb 22, 2016: Allergan Reports Exceptional Fourth Quarter 2015 Continuing Operations Performance with 74% Increase in Net Revenue to $4.2 Billion and 33% Growth in Non-GAAP Diluted EPS to $3.41 295
Corporate Communications 298
Jul 19, 2017: Joseph H. Boccuzi Appointed to Allergan Board of Directors 298
Feb 27, 2017: Lisa DeFrancesco, Vice President of Investor Relations, to Leave Allergan 299
Nov 14, 2016: Adriane M. Brown to Join Allergan Board of Directors 300
Oct 26, 2016: Allergan Announces Changes to Board Leadership 301
Feb 08, 2016: Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction 302
Legal and Regulatory 303
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 303
Mar 30, 2016: Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination 304
Government and Public Interest 305
Jan 23, 2017: Allergan Continues Commitment to Future of Headache Medicine with Educational Grants for Young Neurologists and Research Scientists 305
Product News 306
Sep 07, 2016: Tobira Therapeutics Announces Appointment of Dr. Laurent Fischer as Industry Co-chair of the Liver Forum Steering Committee 306
Aug 10, 2016: RetroSense Therapeutics Completes Low Dose Cohort in Clinical Trial of Novel Gene Therapy Application of Optogenetics 307
Jul 21, 2016: Aptalis Pharma receives CHMP positive opinion on Truberzi (eluxadoline) for the treatment of Irritable Bowel Syndrome 308
Jun 16, 2016: Tobiras Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology 309
Jun 06, 2016: Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer 310
Jun 06, 2016: Chase Pharmaceuticals Continues to Build Its Senior Leadership Team with Appointment of Two Healthcare Industry Veterans 311
May 05, 2016: Glaucoma Drug-Dispensing Eye Insert Shows Promise as New Option for Patients Struggling to Take Daily Prescription Eye Drops 312
May 05, 2016: RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences 313
Apr 21, 2016: Tobira Announces Upcoming Presentations on Biomarkers for NASH at Two Scientific Meetings 314
Apr 08, 2016: Allergan To Present Data on DALVANCE (dalbavancin) at ECCMID 2016 315
Mar 16, 2017: Teva Announces Launch of Authorized Generic of Minastrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) in the United States 316
Product Approvals 317
Jan 29, 2016: Allergans Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder 317
Jan 21, 2016: Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE (dalbavancin) 318
Jan 07, 2016: Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing Cholangitis 319
Clinical Trials 320
Oct 20, 2016: Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting 320
Oct 03, 2016: Tobira Therapeutics Announces Presentations Related to Cenicrivirocs Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting 322
Sep 12, 2016: Tobira Therapeutics Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin 323
Jul 27, 2016: Chase Pharmaceuticals Presents Phase 2 Results for CPC-201 at 2016 Alzheimers Association International Conference 324
Jul 25, 2016: Tobira Therapeutics Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year 325
Jun 27, 2016: Tobiras Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH 327
May 13, 2016: Tobira Therapeutics Announces Publication of Phase 1 Study Results Showing Cenicriviroc Safety in Cirrhotic Patients 328
May 02, 2016: Tobira Announces Interim 12-week Results from the ORION Study 329
Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis 331
Apr 04, 2016: Motus Presents Clinical Proof-of-Concept Results for Relamorelin in the Treatment of Anorexia 332
Mar 16, 2016: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis 333
Mar 09, 2016: Tobira Therapeutics Announces Publication of CENTAUR Phase 2b Study Design and Rationale in Contemporary Clinical Trials 334
Feb 09, 2016: Tobira Therapeutics Completes Patient Recruitment for ORION Phase 2a Study of Cenicriviroc in Obese Patients with Suspected Fatty Liver Disease 335
Jan 21, 2016: VIBERZI (eluxadoline) Phase III Trial Results Published in The New England Journal of Medicine 336
Jan 19, 2016: Rapastinel (GLYX-13) Shown to Improve Ketamine or PCP-Induced Cognitive Impairment in Mice 337
Other Significant Developments 338
Oct 16, 2016: Allergan Demonstrates Ongoing Commitment to Irritable Bowel Syndrome (IBS) with Development of IBS CounSEL 338
Oct 05, 2016: New Study Showcases Economic Impact of Allergans Operations on New Jersey Economy 339
Appendix 341
Methodology 341
About GlobalData 341
Contact Us 341
Disclaimer 341

List Of Tables

Allergan Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 15
Allergan Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 16
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 17
Allergan Plc, Deals By Therapy Area, 2011 to YTD 2017 18
Allergan Plc, Medical Devices Deals, 2011 to YTD 2017 20
Allergan Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 21
Allergan Acquires Rights to LiRIS from TARIS Biomedical for USD588 Million 35
Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 35
Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 37
Actavis Acquires Worldwide Rights To Metronidazole 1.3% Vaginal Gel From Valeant Pharma For US$55 Million 38
Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 39
Watson Pharma Acquires Generic Pharma Products From Perrigo 40
Forest Labs Acquires Worldwide Rights Of Azimilide From Blue Ash Therapeutics 41
Allergan Acquires Distribution Business from Genop Healthcare 42
Chase Pharma Raises USD12 Million in Financing Round 43
Chase Pharma Raises Additional USD0.5 Million in Venture Financing 43
Akarna Therapeutics Raises USD15 Million in Series B Financing 44
RetroSense Therapeutics Raises USD6 Million in Series B Financing Round 45
Chase Pharma Raises USD3 Million in Venture Financing 46
RetroSense Therapeutics Raises USD6 Million in Series A Financing 46
Naurex Raises USD80 Million in Series C Venture Financing 47
Colorescience Raises USD15 Million in Series B Venture Financing 48
Chase Pharma Raises USD21 Million in Series B Financing 49
Naurex Raises US$25 Million In Venture Financing 50
Topokine Therapeutics Raises Funds Through Venture Financing 51
Colorescience Raises US$10 Million In Series A Financing 52
Anterios Raises US$8.5 Million In Venture Financing 53
Anterios Raises US$4.7 Million In Venture Financing 54
Topokine Therapeutics Raises Funds Through Venture Financing 54
Colorescience Raises US$15 Million In Venture Financing 55
Regado Biosciences Raises US$51 Million In Series E Financing 55
Naurex Raises US$38 Million In Series B Financing 57
Uteron Pharma Raises US$10.4 Million In Venture Financing 59
Regado Biosciences Raises US$6.8 Million In Venture Financing 59
Uteron Pharma Raises US$19 Million In Venture Financing 60
SkinMedica Raises US$16.8 Million In Venture Financing 61
KYTHERA BioPharma Secures US$37.42 Million In Series D Financing Round 62
Anterios Secures US$3.1 Million In Venture Financing 63
Regado Biosciences Secures US$11.6 Million In Financing 64
Naurex Secures US$18 Million In Series A Financing Round 64
RetroSense Therapeutics Secures US$0.07 Million In Venture Financing 65
Chase Pharma Secures US$1.2 Million In Venture Financing 66
TPG Capital Acquires Aptalis Pharma from Actavis 66
VMG Partners Invests In Colorescience 67
SRIW Invests US$2 Million In Uteron Pharma 68
Allergan to Enter into Partnership with Target PharmaSolutions 69
Allergan Enters into Agreement with Novartis 69
Gedeon Richter Enters into Distribution Agreement with Allergan 70
T2 Biosystems Enters into Agreement with Allergan 71
Amgen Enters into Agreement with Allergan 71
Allergan Enters into Co-Development Agreement with AstraZeneca 72
Galderma Enters into Agreement with ZELTIQ Aesthetics 73
Allergan Enters into Agreement with Rugen Therapeutics 74
Allergan Enters into Research Agreement with Humana 74
NuMedii Enters into Research Agreement with Allergan 75
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 76
Molecular Partners Reinforces Partnership with Allergan 77
Allergan Enters into Distribution Agreement with WhanIn Pharma 77
Particle Sciences Enters Into Co-Development Agreement With Actavis 78
Voyant Biotherapeutics Enters Into R&D Agreement With Allergan For Ocular Disease 79
Merrimack Pharma Enters Into Co-Development Agreement With Actavis 80
Amerigen Pharma Enters Into Co-Development Agreement With Forest Labs For Specialty Generic Products 81
Actavis Enters Into Co-Marketing Agreement With Valeant Pharma For Zovirax Ointment 81
Actavis Enters Into Co-Promotion Agreement With Valeant Pharma For Zovirax Cream 82
Valeant Pharma Enters Into Co-Promotion Agreement With Actavis For Cordran Tape 83
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 83
Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 84
Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 85
Allergan Enters Into Co-Development Agreement With Molecular Partners 86
Forest Labs Enters Into Co-Development Agreement With Nabriva Therapeutics For BC-3781 87
American Medical Systems Enters Into Co-Development Agreement With Allergan 88
ACADIA Pharma Extends Co-Development Agreement With Allergan 89
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 89
ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 90
Amgen Enters Into Co-Development Agreement With Watson For Generic Cancer Drugs 91
ExonHit Extends Co-Development Agreement With Allergan 93
ACADIA Pharma Extends Drug Discovery Collaboration With Allergan 93
Allergan Enters Into Co-Promotion Agreement With MAP Pharma 94
Regado Biosciences Merges with Tobira Therapeutics 95
Allergan Enters into Licensing Agreement with Assembly Biosciences 96
Allergan Enters into Licensing Agreement with UroGen Pharma 97
Durata Therapeutics Enters into Licensing Agreement with Angelini for Dalvance 98
Forest Labs Enters Into Licensing Agreement With Adamas Pharma For CNS Drug 100
Allergan Enters into Licensing Agreement with AstraZeneca 101
RetroSense Therapeutics Enters into Licensing Agreement with University of California San Diego 102
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 102
Angelini Enters into Licensing Agreement with Allergan 103
Tobira Therapeutics Enters into Licensing Agreement with Dong-A for Evogliptin 104
Dong-A Enters into Licensing Agreement with Tobira Therapeutics for Cenicriviroc 105
Allergan Enters into Licensing Agreement with Heptares Therapeutics 106
Allergan Enters into Licensing Agreement with Mimetogen Pharma 108
Allergan Enters into Licensing Agreement with Almirall for Constella 109
Apricus Biosciences Enters into Licensing Agreement with Allergan 109
Allergan Enters into Licensing Agreement with Merck 110
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 111
Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 112
Kythera Biopharma Terminates Licensing Agreement With Intendis For ATX-101 113
Allergan Enters Into Licensing Agreement With Medytox For Neurotoxin Product 114
Forest Labs Amends Licensing Agreement With moksha8 For Viibryd 115
InnoCore Enters Into Licensing Agreement With Allergan 116
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 117
RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 118
Topokine Therapeutics Enters into Licensing Agreement with University of Bristol 118
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 119
Almirall Enters Into Licensing Agreement With Forest Labs For Aclidinium bromide 120
Watson Pharma Enters Into Licensing Agreement With moksha8 Pharma For Five Generic Central Nervous System Products 121
Forest Labs Enters Into Licensing Agreement With moksha8 For Viibryd 122
Almirall Enters Into Licensing Agreement With Forest Labs For Linaclotide 123
Allergan Enters Into Licensing Agreement With Molecular Partners 124
Furiex Pharma Enters Into Licensing Agreement With Menarini Group For Priligy 125
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 126
QrxPharma Enters Into Licensing Agreement With Actavis For MoxDuo IR 127
Furiex Enters Into Licensing Agreement With Janssen Pharmaceutica For MuDelta 129
RetroSense Therapeutics Enters Into Licensing Agreement With Wayne State University 130
Watson Pharma Enters Into Licensing Agreement With Antares Pharma For Anturol 131
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 132
Allergan Enters Into Licensing Agreement With Molecular Partners For MP0112 132
Durata Therapeutics Enters Into Licensing Agreement For Dalbavancin 133
Furiex Pharma Enters Into Licensing Agreement With Janssen Pharmaceutica For JNJ-Q2 134
Indoco Remedies Extends Licensing Agreement With Watson Pharma For Sterile Products 135
Biovail Labs Enters Into Licensing Agreement With Allergan For Aczone 136
Vitae Pharma Raises USD35 Million in Public Offering of Shares 137
Aptinyx Spin Off from Naurex 139
Tobira Therapeutics Withdraws Registration Statement for Private Placement of Shares for up to USD40 Million 139
Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 140
Anterios Postpones IPO for up to USD54.6 Million 141
Kythera Biopharma Raises USD143.8 Million in Public Offering of Shares 142
Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 144
Actavis Raises USD4.18 Billion in Public Offering of Shares 145
Vitae Pharma Raises USD41 Million in Public Offering of Shares 147
Vitae Pharmaceuticals Completes Exercise of Underwriters Over Allotment Option for IPO for USD63.3 Million 149
Tobira Therapeutics Withdraws IPO 150
Regado Biosciences Completes Public Offering Of Shares For US$60 Million 152
Regado Biosciences Completes Private Placement Of Shares For US$20 Million 153
Furiex Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 154
Kythera Biopharma Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For US$133.5 Million 155
Regado Biosciences Completes Underwriters Exercise Of Over-Allotment Option For IPO For US$43 Million 156
Durata Therapeutics Completes Public Offering Of Shares For US$58 Million 157
Kythera Biopharma Completes Underwriters Exercise Of Over-Allotment Option For US$81 Million 158
MAP Pharma Completes Public Offering Of Common Stock For US$60 Million 160
Forest Labs Plans Rights Offering Of Common Stock 161
Durata Therapeutics Completes IPO For US$78 Million 161
Allergan Raises USD817.8 Million in Public Offering of 0.5% Notes Due 2021 162
Allergan Raises USD599.7 Million in Public Offering of 2.125% Notes Due 2029 163
Allergan Raises USD763.3 Million in Public Offering of Notes Due 2019 165
Allergan Raises USD763.3 Million in Public Offering of 1.25% Notes Due 2024 166
Tobira Therapeutics Raises USD13 Million in Private Placement of Notes 167
Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2045 168
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2016 170
Actavis Raises USD4 Billion in Public Offering of Senior Notes Due 2025 172
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2020 174
Actavis Raises USD1 Billion in Public Offering of Senior Notes Due 2017 176
Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2022 178
Actavis Raises USD3.5 Billion in Public Offering of Senior Notes Due 2020 180
Actavis Raises USD2.5 Billion in Public Offering of Senior Notes Due 2035 182
Actavis Raises USD3 Billion in Public Offering of Senior Notes Due 2018 184
Actavis Raises USD500 Million in Public Offering of Floating Rate Notes Due 2018 186
Forest Lab Completes Private Placement Of Notes Due 2021 For US$750 Million 188
Forest Lab Completes Private Placement Of Notes Due 2019 For US$1.05 Billion 188
Forest Labs Completes Private Placement Of Notes Due 2021 For US$1.2 Billion 189
Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For US$25 Million 190
Watson Pharma Completes Public Offering Of Notes Due 2022 For US$1.7 Billion 191
Watson Pharma Completes Public Offering Of Notes Due 2017 For US$1.2 Billion 192
Watson Pharma Completes Public Offering Of Notes Due 2042 For US$1 Billion 193
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 195
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 196
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 198
AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 200
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 201
Impax Labs Acquires Two Generic Products from Actavis 202
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 203
G&W Labs Acquires Facility in Lincoln County, North Carolina from Actavis 204
Aurobindo Pharma Completes Acquisition Of Generics Operations Of Actavis In Western Europe For US$40.8 Million 204
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 206
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To US$110 Million 207
Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 209
Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 210
Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 211
Harvard Drug Group Completes Acquisition Of Rugby OTC Portfolio Of Watson Pharma For US$117 Million 212
Allergan Enters into Option Arrangement to Acquire Lysosomal Therapeutics 213
Allergan Acquires Motus Therapeutics 214
Allergan Acquires Chase Pharma 215
Allergan Acquires Tobira Therapeutics in Tender Offer 216
Allergan Acquires Vitae Pharma in Tender Offer 218
Teva Pharma Acquires Anda from Allergan for USD500 Million 220
Allergan Acquires Akarna Therapeutics 221
Allergan Acquires RetroSense Therapeutics 222
Allergan to Acquire ForSight VISION5 223
Allergan Acquires Topokine Therapeutics 224
Allergan Acquires Anterios 224
Allergan Acquires Kythera Biopharma for USD2.1 Billion 225
Allergan Acquires Naurex for USD560 Million 227
Actavis Acquires Auden Mckenzie for USD458 Million 228
Actavis Acquires Allergan for USD70.5 Billion 229
Actavis May Acquire Almirall 230
Actavis Acquires Durata Therapeutics for USD675 Million in Tender Offer 231
Pfizer May Acquire Actavis 233
Forest Labs Completes Acquisition of Furiex Pharma 234
Actavis Completes Acquisition of Forest Labs for USD28 Billion 235
Actavis Acquires Silom Medical For US$100 Million 237
Forest Lab Completes Acquisition Of Aptalis Pharma From TPG Capital For US$2.9 Billion 238
Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 240
AstraZeneca Rumored To Acquire Forest Labs For US$15 Billion 241
Actavis Completes Acquisition Of Warner Chilcott For US$8.5 Billion 241
Actavis Completes Acquisition Of Remaining 26.7% Stake In Zdravlje For Up To US$9.1 Million 244
Allergan Completes Acquisition Of MAP Pharma For US$958 Million 245
Watson Pharma Acquires Uteron Pharma, Womens Health Company, For Up To US$305 Million 246
Allergan Completes Acquisition Of SkinMedica, Skin Products Maker, For US$350 Million 248
Watson Pharma Completes Acquisition Of Actavis Group For US$5.92 Billion 250
Watson Pharma Sells Minority Stake In moksha8 Pharma For US$47 Million 252
Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For US$394 Million 253
SkinMedica Acquires Colorescience, Maker Of Skincare Products 255
Allergan Completes Acquisition Of Vicept Therapeutics 256
High River Acquires 6.5% Stake In Forest Labs 257
Watson Pharma Acquires Specifar Pharma 257
Forest Labs Completes Acquisition Of Clinical Data 259
Allergan Plc, Key Competitors 262
Allergan Plc, Key Employees 263
Allergan Plc, Other Locations 264
Allergan Plc, Subsidiaries 264

List Of Figures

Allergan Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 15
Allergan Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 16
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 17
Allergan Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 18
Allergan Plc, Medical Devices Deals, 2011 to YTD 2017 20

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available